Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Thyroid Gland Papillary Carcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Thyroid Gland Carcinoma (344
)
Thyroid Gland Anaplastic Carcinoma (62
)
Thyroid Gland Medullary Carcinoma (58
)
Thyroid Gland Follicular Carcinoma (25
)
Thyroid Gland Hurthle Cell Carcinoma (12
)
Thyroid Gland Carcinoma (344
)
Thyroid Gland Anaplastic Carcinoma (62
)
Thyroid Gland Medullary Carcinoma (58
)
Thyroid Gland Follicular Carcinoma (25
)
Thyroid Gland Hurthle Cell Carcinoma (12
)
›
Associations
(55)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
BRAF V600E
Thyroid Gland Papillary Carcinoma
BRAF V600E
Thyroid Gland Papillary Carcinoma
vemurafenib
Sensitive: C1 - Off-label
J Transl Med - 3 weeks (New D)
vemurafenib
Sensitive
:
C1
J Transl Med - 3wk
vemurafenib
Sensitive: C1 - Off-label
J Transl Med - 3 weeks
vemurafenib
Sensitive
:
C1
J Transl Med - 3 weeks - (New D)
BRAF V600E
Thyroid Gland Papillary Carcinoma
BRAF V600E
Thyroid Gland Papillary Carcinoma
dabrafenib
Sensitive: C1 - Off-label
J Transl Med - 3 weeks (New D)
dabrafenib
Sensitive
:
C1
J Transl Med - 3wk
dabrafenib
Sensitive: C1 - Off-label
J Transl Med - 3 weeks
dabrafenib
Sensitive
:
C1
J Transl Med - 3 weeks - (New D)
No biomarker
Thyroid Gland Papillary Carcinoma
No biomarker
Thyroid Gland Papillary Carcinoma
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Papillary Carcinoma
No biomarker
Thyroid Gland Papillary Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
NTRK2 fusion
Thyroid Gland Papillary Carcinoma
NTRK2 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
No biomarker
Thyroid Gland Papillary Carcinoma
No biomarker
Thyroid Gland Papillary Carcinoma
denosumab
Sensitive: A2 - Guideline
denosumab
Sensitive
:
A2
denosumab
Sensitive: A2 - Guideline
denosumab
Sensitive
:
A2
RET fusion
Thyroid Gland Papillary Carcinoma
RET fusion
Thyroid Gland Papillary Carcinoma
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Papillary Carcinoma
NTRK3 fusion
Thyroid Gland Papillary Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Papillary Carcinoma
NTRK2 fusion
Thyroid Gland Papillary Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Papillary Carcinoma
NTRK1 fusion
Thyroid Gland Papillary Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Papillary Carcinoma
NTRK3 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Papillary Carcinoma
NTRK1 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
TMB-H
Thyroid Gland Papillary Carcinoma
TMB-H
Thyroid Gland Papillary Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
RET fusion
Thyroid Gland Papillary Carcinoma
RET fusion
Thyroid Gland Papillary Carcinoma
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
No biomarker
Thyroid Gland Papillary Carcinoma
No biomarker
Thyroid Gland Papillary Carcinoma
cabozantinib tablet
Sensitive: A2 - Guideline
cabozantinib tablet
Sensitive
:
A2
cabozantinib tablet
Sensitive: A2 - Guideline
cabozantinib tablet
Sensitive
:
A2
BRAF V600E
Thyroid Gland Papillary Carcinoma
BRAF V600E
Thyroid Gland Papillary Carcinoma
trametinib + dabrafenib
Sensitive: C1 - Off-label
trametinib + dabrafenib
Sensitive
:
C1
trametinib + dabrafenib
Sensitive: C1 - Off-label
trametinib + dabrafenib
Sensitive
:
C1
BRAF V600
Thyroid Gland Papillary Carcinoma
BRAF V600
Thyroid Gland Papillary Carcinoma
vemurafenib + cobimetinib
Sensitive: C1 - Off-label
vemurafenib + cobimetinib
Sensitive
:
C1
vemurafenib + cobimetinib
Sensitive: C1 - Off-label
vemurafenib + cobimetinib
Sensitive
:
C1
BRAF V600E
Thyroid Gland Papillary Carcinoma
BRAF V600E
Thyroid Gland Papillary Carcinoma
vemurafenib + cobimetinib
Sensitive: C1 - Off-label
vemurafenib + cobimetinib
Sensitive
:
C1
vemurafenib + cobimetinib
Sensitive: C1 - Off-label
vemurafenib + cobimetinib
Sensitive
:
C1
BRAF mutation
Thyroid Gland Papillary Carcinoma
BRAF mutation
Thyroid Gland Papillary Carcinoma
vemurafenib
Sensitive: C2 – Inclusion Criteria
vemurafenib
Sensitive
:
C2
vemurafenib
Sensitive: C2 – Inclusion Criteria
vemurafenib
Sensitive
:
C2
BRAF mutation
Thyroid Gland Papillary Carcinoma
BRAF mutation
Thyroid Gland Papillary Carcinoma
FORE-8394 + cobicistat
Sensitive: C3 – Early Trials
FORE-8394 + cobicistat
Sensitive
:
C3
FORE-8394 + cobicistat
Sensitive: C3 – Early Trials
FORE-8394 + cobicistat
Sensitive
:
C3
BRAF V600
Thyroid Gland Papillary Carcinoma
BRAF V600
Thyroid Gland Papillary Carcinoma
BGB-283
Sensitive: C3 – Early Trials
BGB-283
Sensitive
:
C3
BGB-283
Sensitive: C3 – Early Trials
BGB-283
Sensitive
:
C3
BRAF mutation
Thyroid Gland Papillary Carcinoma
BRAF mutation
Thyroid Gland Papillary Carcinoma
dabrafenib
Sensitive: C3 – Early Trials
dabrafenib
Sensitive
:
C3
dabrafenib
Sensitive: C3 – Early Trials
dabrafenib
Sensitive
:
C3
RET fusion
Thyroid Gland Papillary Carcinoma
RET fusion
Thyroid Gland Papillary Carcinoma
cabozantinib tablet
Sensitive: C3 – Early Trials
cabozantinib tablet
Sensitive
:
C3
cabozantinib tablet
Sensitive: C3 – Early Trials
cabozantinib tablet
Sensitive
:
C3
BRAF mutation
Thyroid Gland Papillary Carcinoma
BRAF mutation
Thyroid Gland Papillary Carcinoma
trametinib + dabrafenib
Sensitive: C3 – Early Trials
trametinib + dabrafenib
Sensitive
:
C3
trametinib + dabrafenib
Sensitive: C3 – Early Trials
trametinib + dabrafenib
Sensitive
:
C3
BRAF V600
Thyroid Gland Papillary Carcinoma
BRAF V600
Thyroid Gland Papillary Carcinoma
FORE-8394
Sensitive: C3 – Early Trials
FORE-8394
Sensitive
:
C3
FORE-8394
Sensitive: C3 – Early Trials
FORE-8394
Sensitive
:
C3
BRAF V600E
Thyroid Gland Papillary Carcinoma
BRAF V600E
Thyroid Gland Papillary Carcinoma
siltuximab
Sensitive: C4 – Case Studies
siltuximab
Sensitive
:
C4
siltuximab
Sensitive: C4 – Case Studies
siltuximab
Sensitive
:
C4
PDGFRB overexpression
Thyroid Gland Papillary Carcinoma
PDGFRB overexpression
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: C4 – Case Studies
larotrectinib
Sensitive
:
C4
larotrectinib
Sensitive: C4 – Case Studies
larotrectinib
Sensitive
:
C4
EGFR overexpression
Thyroid Gland Papillary Carcinoma
EGFR overexpression
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: C4 – Case Studies
larotrectinib
Sensitive
:
C4
larotrectinib
Sensitive: C4 – Case Studies
larotrectinib
Sensitive
:
C4
BRAF V600
Thyroid Gland Papillary Carcinoma
BRAF V600
Thyroid Gland Papillary Carcinoma
dabrafenib + SNR1611
Sensitive: C4 – Case Studies
dabrafenib + SNR1611
Sensitive
:
C4
dabrafenib + SNR1611
Sensitive: C4 – Case Studies
dabrafenib + SNR1611
Sensitive
:
C4
NCOA4-RET fusion
Thyroid Gland Papillary Carcinoma
NCOA4-RET fusion
Thyroid Gland Papillary Carcinoma
lenvatinib
Sensitive: C4 – Case Studies
lenvatinib
Sensitive
:
C4
lenvatinib
Sensitive: C4 – Case Studies
lenvatinib
Sensitive
:
C4
TPM3-NTRK1 fusion
Thyroid Gland Papillary Carcinoma
TPM3-NTRK1 fusion
Thyroid Gland Papillary Carcinoma
AB-106
Sensitive: C4 – Case Studies
AB-106
Sensitive
:
C4
AB-106
Sensitive: C4 – Case Studies
AB-106
Sensitive
:
C4
GLI3 overexpression
Thyroid Gland Papillary Carcinoma
GLI3 overexpression
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: C4 – Case Studies
larotrectinib
Sensitive
:
C4
larotrectinib
Sensitive: C4 – Case Studies
larotrectinib
Sensitive
:
C4
GLI2 overexpression
Thyroid Gland Papillary Carcinoma
GLI2 overexpression
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: C4 – Case Studies
larotrectinib
Sensitive
:
C4
larotrectinib
Sensitive: C4 – Case Studies
larotrectinib
Sensitive
:
C4
GLI1 overexpression
Thyroid Gland Papillary Carcinoma
GLI1 overexpression
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: C4 – Case Studies
larotrectinib
Sensitive
:
C4
larotrectinib
Sensitive: C4 – Case Studies
larotrectinib
Sensitive
:
C4
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login